Afimetoran

Generic Name
Afimetoran
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C26H32N6O
CAS Number
2171019-55-7
Unique Ingredient Identifier
LXP7MZL0VF
Background

Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8. It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

First Posted Date
2023-06-13
Last Posted Date
2024-08-07
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
65
Registration Number
NCT05901714
Locations
πŸ‡ΊπŸ‡Έ

Local Institution - 0001, Miami, Florida, United States

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

Phase 1
Recruiting
Conditions
Healthy Volunteers
Interventions
Drug: Famotidine
Drug: Afimetoran
First Posted Date
2023-05-19
Last Posted Date
2024-01-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
76
Registration Number
NCT05866627
Locations
πŸ‡¬πŸ‡§

Quotient Sciences, Nottingham, United Kingdom

A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: BMS-986256
Drug: Famotidine
First Posted Date
2021-06-28
Last Posted Date
2022-01-21
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
22
Registration Number
NCT04941755
Locations
πŸ‡ΊπŸ‡Έ

PPD Development, LP, Austin, Texas, United States

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Phase 2
Recruiting
Conditions
Systemic Lupus Erythematosus
Interventions
Drug: Afimetoran
Other: Placebo
First Posted Date
2021-05-20
Last Posted Date
2024-11-22
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
268
Registration Number
NCT04895696
Locations
πŸ‡ΊπŸ‡Έ

Local Institution - 0137, South Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States

πŸ‡ΊπŸ‡Έ

Clinical Research of West Florida, Inc. (Clearwater), Clearwater, Florida, United States

and more 170 locations

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

First Posted Date
2020-07-30
Last Posted Date
2023-05-09
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
13
Registration Number
NCT04493541
Locations
πŸ‡©πŸ‡ͺ

Local Institution - 0001, Berlin, Germany

Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: BMS-986256
Drug: Famotidine
First Posted Date
2020-07-14
Last Posted Date
2022-01-11
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
35
Registration Number
NCT04470778
Locations
πŸ‡ΊπŸ‡Έ

ICON (PRA Health Sciences) - Salt Lake, Salt Lake City, Utah, United States

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: BMS-986256
Drug: Milk of magnesia
First Posted Date
2020-02-13
Last Posted Date
2022-01-10
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
8
Registration Number
NCT04269356
Locations
πŸ‡ΊπŸ‡Έ

Covance - Clinical Pharmacology Services - Madison, Madison, Wisconsin, United States

Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil

First Posted Date
2019-07-31
Last Posted Date
2020-06-16
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
15
Registration Number
NCT04039373
Locations
πŸ‡ΊπŸ‡Έ

PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: BMS-986256
Drug: Loestrin
First Posted Date
2019-07-11
Last Posted Date
2022-05-31
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
32
Registration Number
NCT04016753
Locations
πŸ‡ΊπŸ‡Έ

Altasciences Los Angeles (Formerly WCCT Global), Cypress, California, United States

A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: BMS-986256
Drug: Itraconazole
First Posted Date
2019-05-15
Last Posted Date
2020-02-25
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
15
Registration Number
NCT03950960
Locations
πŸ‡ΊπŸ‡Έ

PRA Health Sciences - Lenexa, Lenexa, Kansas, United States

Β© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy